BLTE יחס מהיר Belite Bio Inc

Belite Bio, Inc (BLTE) is facing a capital shortage due to the costs of final drug trials, while simultaneously developing a cutting-edge ophthalmological environment to combat retinal degeneration. This quick ratio chart demonstrates financial stability, where 48.93 represents the current value of the metric. The development of targeted therapy guarantees stable demand and long-term profit growth, as confirmed by the indicator's price action.

The quick ratio measures a company's ability to meet short-term obligations using cash and accounts receivable, completely excluding illiquid inventories. By analyzing the quick ratio indicator on GURU.Markets, an investor sees the current value of 48.93, which is critically important for Belite Bio, Inc (BLTE), as the costly sterile logistics of drugs require a constant availability of liquid cash to ensure uninterrupted supplies.